S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
NASDAQ:CLSN

Imunon - CLSN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$1.95
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
CLSN stock logo

About Imunon (NASDAQ:CLSN) Stock

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Stock News Headlines

Recap: Celsion Q2 Earnings - Benzinga
Celsion Q2 2022 Earnings Preview
See More Headlines

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Company Calendar

Last Earnings
8/15/2022
Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSN
Employees
27
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$9.66 per share

Miscellaneous

Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links


Key Executives

  • Mr. Michael H. Tardugno (Age 71)
    Exec. Chairman
    Comp: $1.01M
  • Mr. Jeffrey W. Church CPA (Age 65)
    CPA, CFO, Exec. VP & Corp. Sec.
    Comp: $528.54k
  • Dr. Khursheed Anwer M.B.A. (Age 62)
    Ph.D., Exec. VP & Chief Scientific Officer
    Comp: $511.92k
  • Dr. Nicholas Borys (Age 63)
    Exec. VP & Chief Medical Officer
    Comp: $586.54k
  • Dr. Corinne Le Goff M.B.A.
    Pharm.D., CEO, Pres & Director
  • Mr. Timothy J. Tumminello (Age 64)
    Chief Accounting Officer & Controller
  • Ms. Marianne M. Lambertson
    VP of Communications & Investor Relations













CLSN Stock - Frequently Asked Questions

Should I buy or sell Imunon stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSN shares.
View CLSN analyst ratings
or view top-rated stocks.

What is Imunon's stock price forecast for 2023?

1 brokers have issued twelve-month price targets for Imunon's stock. Their CLSN share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next year.
View analysts price targets for CLSN
or view top-rated stocks among Wall Street analysts.

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) posted its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same period in the previous year, the business earned ($0.90) EPS.

When did Imunon's stock split?

Shares of Imunon reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?
What is Imunon's stock symbol?

Imunon trades on the NASDAQ under the ticker symbol "CLSN."

How much money does Imunon make?

Imunon (NASDAQ:CLSN) has a market capitalization of $0.00 and generates $500,000.00 in revenue each year.

How can I contact Imunon?

Imunon's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The official website for the company is www.celsion.com. The biotechnology company can be reached via phone at (609) 896-9100, via email at jchurch@celsion.com, or via fax at 609-896-2200.

This page (NASDAQ:CLSN) was last updated on 12/8/2022 by MarketBeat.com Staff